Upstream process development is a critical step in ensuring that the needed protein quality is met on a large scale. However, due to the inherent properties of the selected clone, the Research Production Cell Banks, which are derived mainly based on initial high productivity, frequently delay the subsequent process development. In the cell line development stage, we recently used the CHOZN-GS system to apply our quality-driven Fc-fusion protein screening procedures to select appropriate clones that ranged in the target product quality. Our strategies can also be used as an enhanced cell line development platform with high titer and developability.
In this webinar, you will learn:
Dr. Young Min Oh
Since 2017, Dr. Young Min has worked for GI Innovation, Inc. as the head of SMART division and co-founder. His main activity is the construction of SMART platform technology, which is comprised of the screening & selection method for an 'easy-to-express protein' structure with the therapeutic function of a target disease and its stable high production cell line development. He holds a doctorate degree in Immunology from POSTECH, South Korea, where he focused on the study of the transcriptional regulatory network during inflammation through comparative genomics and systems biology interpretation.